tbuckley/cabot-search huggingface dataset:
737P Phase II study of IV vinorelbine in relapsed platinum resistant or refractory C5 high grade serous primary peritoneal, fallopian tube or ovarian cancer (VIP)
Authors: N.Y.L. Ngoi, T.Z. Tan, K.T. Kuay, A.C.Y. Tan, J.Y. Lee, M.Y. Pang, K.W. Tham, J. Chan, W.L. Wong, W.Y. Chay, D. Anne, M. Friedlander, S. Varma, T. Meniawy, G. Au-Yeung, C. Scott, L. Mileshkin, D. Bowtell, R.Y-J. Huang, D.S.P. Tan
Journal: Annals of Oncology (2021)
Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol 2021;79:783–92
Authors: Xiaoshuai Gao, Guo Chen, Xin Wei
Journal: European Urology (2021)
LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
Authors: G.N. Hortobagyi, S.M. Stemmer, H.A. Burris, Y.S. Yap, G.S. Sonke, L. Hart, M. Campone, K. Petrakova, E.P. Winer, W. Janni, P.F. Conte, D. Cameron, F. André, C. Arteaga, J.P. Zarate, A. Chakravartty, T. Taran, F. Le Gac, P. Serra, J. O'Shaughnessy
Journal: Annals of Oncology (2021)
Trends in UK meat consumption: analysis of data from years 1–11 (2008–09 to 2018–19) of the National Diet and Nutrition Survey rolling programme
Authors: Cristina Stewart, Carmen Piernas, Brian Cook, Susan A Jebb
Journal: The Lancet Planetary Health (2021)

BackgroundHigh meat consumption, particularly red meat and processed meat, negatively affects our health, while meat production is one of the largest contributors to global warming and environmental degradation. The aim of our study was to explore trends in meat consumption within the UK and the associated changes in environmental impact. We also aimed to identify any differences in intake associated with gender, ethnicity, socioeconomic status, and year of birth.MethodsOur study aimed to describe consumption of red, white, and processed meat within the UK, using data from the National Diet and Nutrition Survey rolling programme (2008–09 to 2018–19), and the associated changes in environmental impact. Meat consumption was based on disaggregated meat data, from 4 day food diaries that excluded all non-meat components of composite dishes. For each year surveyed, trends for meat intake were reported as mean grams per capita per day and linear-regression models were used to test for trends. We used multivariable linear-regression models to examine differences among consumers, as a percentage of food energy, by gender, ethnicity, equivalised household income, and year of birth.FindingsFrom 2008 to 2019, average meat consumption per capita per day decreased from 103·7 g (SE 2·3) to 86·3 g (2·9) per day (ptrend<0·0001), including an absolute reduction in red-meat consumption of 13·7 g (ptrend<0·0001), an absolute reduction in processed meat consumption of 7·0 g (ptrend<0·0001), and a 3·2 g increase (ptrend=0·0027) in white-meat consumption. Collectively, these changes were associated with a significant reduction in all six environmental indicators over the whole period. The two middle birth-year groups (people born in 1960–79 and 1980–99) and White individuals were the highest meat consumers. Meat intake increased over time among people born after 1999, was unchanged among Asian and Asian British populations, and decreased in all other population subgroups. We found no difference in intake with gender or household income.InterpretationDespite the overall reduction in meat intake, reaching meat-consumption targets that align with sustainable diets will require a substantial acceleration of this trend.FundingThe Wellcome Trust, Our Planet Our Health programme (Livestock, Environment, and People).
1252P Liquid biopsy to track KRAS G12C mutation at progressive disease in patients with advanced non-small cell lung cancer (NSCLC)
Authors: G. De Renzi, C. Nicolazzo, S. Pisegna, F. Belardinilli, I. Bottillo, P. Grammatico, G. Giannini, A.J. Gelibter, P. Gazzaniga
Journal: Annals of Oncology (2021)
267P Phase Ib/II open-label, randomized evaluation of second- or third-line (2L/3L) atezolizumab (atezo) + entinostat (entino) in MORPHEUS-HR+ breast cancer (M-HR+BC)
Authors: A. Sonnenblick, S-A. Im, K.S. Lee, A. Tan, M. Telli, S. Strulov Shachar, F. Bene Tchaleu, E. Cha, K. DuPree, M. Nikanjam, C. Shemesh, J. Xu, X. Zhang, J. Zhu, H.S. Rugo
Journal: Annals of Oncology (2021)
46P Intraperitoneal perfusion with sodium bicarbonate solution can significantly increase the lifespan of mice with Ehrlich ascites carcinoma
Authors: A.A. Bogdanov, N.A. Verlov, N.A. Knyazev, V.V. Klimenko, A.A. Bogdanov, V.M. Moiseyenko
Journal: Annals of Oncology (2021)
95P Optimizing selection of experimental treatment for patients with advanced cancer using whole genome sequencing
Authors: M. Pruis, F. Groenendijk, S. Badloe, A. van Puffelen, D. Robbrecht, W. Dinjens, S. Sleijfer, J. von der Thüsen, P. Roepman, M.P. Lolkema
Journal: Annals of Oncology (2021)
The Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the Discovery, Prediction, and Exploration of Mutational Signatures
Authors: Aaron Chevalier, Shiyi Yang, Zainab Khurshid, Nathan Sahelijo, Tong Tong, Jonathan H. Huggins, Masanao Yajima, Joshua D. Campbell
Journal: Cancer Research (2021)

Abstract Mutational signatures are patterns of somatic alterations in the genome caused by carcinogenic exposures or aberrant cellular processes. To provide a comprehensive workflow for preprocessing, analysis, and visualization of mutational signatures, we created the Mutational Signature Comprehensive Analysis Toolkit (musicatk) package. musicatk enables users to select different schemas for counting mutation types and to easily combine count tables from different schemas. Multiple distinct methods are available to deconvolute signatures and exposures or to predict exposures in individual samples given a pre-existing set of signatures. Additional exploratory features include the ability to compare signatures to the Catalogue Of Somatic Mutations In Cancer (COSMIC) database, embed tumors in two dimensions with uniform manifold approximation and projection, cluster tumors into subgroups based on exposure frequencies, identify differentially active exposures between tumor subgroups, and plot exposure distributions across user-defined annotations such as tumor type. Overall, musicatk will enable users to gain novel insights into the patterns of mutational signatures observed in cancer cohorts. Significance: The musicatk package empowers researchers to characterize mutational signatures and tumor heterogeneity with a comprehensive set of preprocessing utilities, discovery and prediction tools, and multiple functions for downstream analysis and visualization.
Integrated single-cell transcriptomics and epigenomics reveals strong germinal center–associated etiology of autoimmune risk loci
Authors: Hamish W. King, Kristen L. Wells, Zohar Shipony, Arwa S. Kathiria, Lisa E. Wagar, Caleb Lareau, Nara Orban, Robson Capasso, Mark M. Davis, Lars M. Steinmetz, Louisa K. James, William J. Greenleaf
Journal: Science Immunology (2021)

The germinal center (GC) response is critical for both effective adaptive immunity and establishing peripheral tolerance by limiting autoreactive B cells. Dysfunction in these processes can lead to defective immune responses to infection or contribute to autoimmune disease. To understand the gene regulatory principles underlying the GC response, we generated a single-cell transcriptomic and epigenomic atlas of the human tonsil, a widely studied and representative lymphoid tissue. We characterize diverse immune cell subsets and build a trajectory of dynamic gene expression and transcription factor activity during B cell activation, GC formation, and plasma cell differentiation. We subsequently leverage cell type–specific transcriptomic and epigenomic maps to interpret potential regulatory impact of genetic variants implicated in autoimmunity, revealing that many exhibit their greatest regulatory potential in GC-associated cellular populations. These included gene loci linked with known roles in GC biology (
787P Endotoxicosis and properties of erythrocyte membranes in patients with cervical cancer receiving combination therapy with dendritic cell-based immunotherapy
Authors: I.A. Goroshinskaya, A.P. Menshenina, E.M. Frantsiyants, T.I. Moiseenko, E.V. Verenikina, L.A. Nemashkalova, O.G. Selezneva, A.A. Cherkasova, L.Y. Vladimirova
Journal: Annals of Oncology (2021)
1640P Impact of COVID-19 vaccination campaign on psychological status in cancer patients (pts)
Authors: D. Tregnago, S. Pilotto, L. Belluomini, J. Menis, E. Fiorio, M. Pavarana, M. Casali, L. Benini, F. Zacchi, A. Caldart, E. Trevisani, I. Trestini, A. Avancini, D. Cafaro, C. Cadorin, M. Rimondini, L. Del Piccolo, S. Zuliani, M. Milella
Journal: Annals of Oncology (2021)
Transanal Drainage Tubes—Prevention of Leaks or Unnecessary Sump?
Authors: David B. Stewart
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management
Authors: Michael S. Leapman, Rong Wang, Henry S. Park, James B. Yu, Preston C. Sprenkle, Michaela A. Dinan, Xiaomei Ma, Cary P. Gross
Journal: JAMA Network Open (2021)

The clinical decisions that arise from prostate magnetic resonance imaging (MRI) and genomic testing in patients with prostate cancer are not well understood.To evaluate the association between regional uptake of prostate MRI and genomic testing and observation vs treatment for prostate cancer.This retrospective cohort study of commercial insurance claims for prostate MRI and genomic testing included 65 530 patients 40 to 89 years of age newly diagnosed with prostate cancer from July 1, 2012, through June 30, 2019.Patient- and regional-level use of prostate MRI and genomic testing.Observation vs definitive treatment for prostate cancer. Patient-level analyses examined the association between receipt of testing or residing in a hospital referral region (HRR) that adopted testing and observation. In regional-level analyses, the dependent variable was the change in the proportion of patients observed for prostate cancer at the HRR level between 2 periods: July 1, 2012, to June 30, 2014, and July 1, 2017, to June 20, 2019. The independent study variables included HRR-level changes in the proportion of men undergoing prostate MRI and genomic testing between these periods, and the models were adjusted for contextual factors associated with prostate cancer care and socioeconomic status.This study identified 65 530 patients, including 27 679 in the early period (mean [SD] age, 58.0 [5.9] years) and 37 851 in the late period (mean [SD] age, 59.0 [5.7] years). Use of prostate MRI increased significantly from 7.2% (95% CI, 6.9%-7.5%) to 16.7% (95% CI, 16.3%-17.1%) from the early to late period. Use of genomic testing increased significantly from 1.3% (95% CI, 1.1%-1.4%) to 12.7% (95% CI, 12.3%-13.0%) from the early to late period. Compared with the lowest, the highest HRR quartiles of prostate MRI and genomic testing uptake were associated with an adjusted 4.1% (SE, 1.1%; P < .001) and 2.5% (SE, 1.1%; P = .03) absolute increase in the proportion of patients receiving observation, respectively.In this cohort study, uptake of prostate MRI and genomic testing was associated with increased use of initial observation vs treatment for prostate cancer. Marked geographic variation supports the need for further patient-level research to optimize the dissemination and outcome of testing.
Liver transplantation for alcohol-related liver disease in the UK: revised UK Liver Advisory Group recommendations for referral
Authors: Steven Masson, Helen Aldersley, Joanna A Leithead, Ed Day, Andrew Langford, Pamela Healy, John O'Grady, Douglas Thorburn, Charlotte Parker, Liz Shepherd, Katherine Arndtz, Kerry Webb, Andrew Holt
Journal: The Lancet. Gastroenterology & hepatology (2021)
Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial
Authors: Vishal C. Patel, Sunjae Lee, Mark J.W. McPhail, Kevin Da Silva, Susie Guilly, Ane Zamalloa, Elizabeth Witherden, Sidsel Støy, Godhev Kumar Manakkat Vijay, Nicolas Pons, Nathalie Galleron, Xaiohong Huang, Selin Gencer, Muireann Coen, Thomas Henry Tranah, Julia Alexis Wendon, Kenneth D. Bruce, Emmanuelle Le Chatelier, Stanislav Dusko Ehrlich, Lindsey Ann Edwards, Saeed Shoaie, Debbie Lindsay Shawcross
Journal: Journal of Hepatology (2021)

Rifaximin-α is efficacious for the prevention of recurrent hepatic encephalopathy (HE), but its mechanism of action remains unclear. We postulated that rifaximin-α reduces gut microbiota-derived endotoxemia and systemic inflammation, a known driver of HE.
644TiP SAABR: Single arm phase II study of abiraterone + atezolizumab + GnRH analog and stereotactic body radiotherapy (SBRT) to the prostate in men with newly diagnosed hormone-sensitive metastatic prostate cancer (mHSPC)
Authors: D.E. Rathkopf, B. Decker, P. Schum, S. McBride
Journal: Annals of Oncology (2021)
Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR
Authors: Roberta D’Ambrosio, Elisabetta Degasperi, Maria Paola Anolli, Ilaria Fanetti, Marta Borghi, Roberta Soffredini, Massimo Iavarone, Giulia Tosetti, Riccardo Perbellini, Angelo Sangiovanni, Vana Sypsa, Pietro Lampertico
Journal: Journal of Hepatology (2021)
合成および生物学的疾患修飾性抗リウマチ薬による関節リウマチ管理に関するEULAR(欧州リウマチ学会)推奨事項: 2013年最新情報
Authors: Smolen Josef S, Landewe Robert, Breedveld Ferdinand C, Buch Maya, Burmester Gerd, Dougados Maxime, Emery Paul, Gaujoux-Viala Cecile, Gossec Laure, Nam Jackie, Ramiro Sofia, Winthrop Kevin, DE Wit Maarten, Aletaha Daniel, Betteridge Neil, Bijlsma Johannes W J, Boers Maarten, Buttgereit Frank, Combe Bernard, Cutolo Maurizio, Damjanov Nemanja, Hazes Johanna M W, Kouloumas Marios, Kvien Tore K, Mariette Xavier, Pavelka Karel, Van Riel Piet L C M, Rubbert-Roth Andrea, Scholte-Voshaar Marieke, Scott David L, Sokka-Isler Tuulikki, Wong John B
Journal: Annals of the Rheumatic Diseases (2014)
Acute and sustained increase in endothelial biomarkers in COVID-19
Authors: Raúl Méndez, Paula González-Jiménez, Ana Latorre, Mónica Piqueras, Leyre Bouzas, Katheryn Yépez, Ana Ferrando, Enrique Zaldívar-Olmeda, Antonio Moscardó, Ricardo Alonso, Soledad Reyes, Rosario Menéndez
Journal: Thorax (2021)

Endothelial injury is related to poor outcomes in respiratory infections yet little is known in relation to COVID-19. Performing a longitudinal analysis (on emergency department admission and post-hospitalisation follow-up), we evaluated endothelial damage via surrogate systemic endothelial biomarkers, that is, proadrenomedullin (proADM) and proendothelin, in patients with COVID-19. Higher proADM and/or proendothelin levels at baseline were associated with the most severe episodes and intensive care unit admission when compared with ward-admitted individuals and outpatients. Elevated levels of proADM or proendothelin at day 1 were associated with in-hospital mortality. High levels maintained after discharge were associated with reduced diffusing capacity.
SO-16 Quality of life in Finnish metastatic colorectal cancer patients actively treated with the aim of maximizing resection and/or local ablative therapy (RAXO-study NCT01531595)
Authors: P. Osterlund, H. Stedt, K. Lehtomäki, E. Osterlund, T. Muhonen, L. Soveri, P. Halonen, T. Salminen, R. Kallio, A. Ålgars, E. Heervä, A. Lamminmäki, A. Uutela, T. Luukkaala, S. Aho, J. Lehto, T. Saarto, N. Färkkilä, A. Nordin, B. Glimelius, H. Isoniemi, R. Ristamäki
Journal: Annals of Oncology (2021)
Proton export alkalinizes intracellular pH and reprograms carbon metabolism to drive normal and malignant cell growth
Authors: Cheuk Him Man, Francois E. Mercier, Nian Liu, Wentao Dong, Gregory Stephanopoulos, Li Jiang, Yookyung Jung, Charles P. Lin, Anskar Y. H. Leung, David T. Scadden
Journal: Blood (2021)
LBA64 Olanzapine, an alternative to dexamethasone for preventing nausea and vomiting induced by cisplatin-based doublet highly emetogenic chemotherapy: A non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial
Authors: Z. Liu, Y. Zhou, W-N. Feng, M-Y. Chen, G. Han, G-R. Zou, S. Yang, Y. He, X. Zou, J. Tang, L. Zhang, L. Cui, H. Chen, G. Li, S. Jiang, J. Gao, L. Xiao, Q. Zhang, W. Yi, C. Huang
Journal: Annals of Oncology (2021)
Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin
Authors: Wellbert Hernández-Núñez, Jesús Zacarías Villareal-Pérez, René Rodríguez-Gutiérrez
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis
Authors: Ignatius Ryan Adriawan, Faranaz Atschekzei, Oliver Dittrich-Breiholz, Panagiotis Garantziotis, Stefanie Hirsch, Linus Maximillian Risser, Maike Kosanke, Reinhold Ernst Schmidt, Torsten Witte, Georgios Sogkas
Journal: Annals of the Rheumatic Diseases (2021)

Giant cell arteritis (GCA) is the most common primary vasculitis, preferentially affecting the aorta and its large-calibre branches. An imbalance between proinflammatory CD4
862MO Gene expression profile differentiates short-term and long-term survivors with immunotherapy in patients with recurrent/metastatic head and neck cancer
Authors: P. Bossi, C. Gurizzan, M. Airoldi, M. Cossu Rocca, P. Strojan, G.K. Cvetka, M.C. Merlano, N. Denaro, F. Caponigro, F. Perri, A. Argiris, L.F. Licitra, M.S. Serafini, L. De Cecco
Journal: Annals of Oncology (2021)
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study
Authors: Sarah C Rutherford, Jeremy S Abramson, Nancy L Bartlett, Stefan K Barta, Nadia Khan, Robin Joyce, Kami Maddocks, Trisha Ali-Shaw, Silvia Senese, Ying Yuan, Jason Westin, John P Leonard
Journal: The Lancet Haematology (2021)
1686P Selecting patient-reported outcomes to monitor symptomatic toxicities of immune-checkpoint inhibitors: A Delphi study
Authors: A.M.D.S. Lopes, S. Colomer-Lahiguera, N-N. Mederos-Alfonso, V. Aedo Lopez, G. Spurrier-Bernard, L.K. Tolstrup, H. Pappot, S. Aspeslagh, A. Rogiers, B. Neyns, J.B.A.G. Haanen, S.A. Mitchell, A. Addeo, O.A. Michielin, M. Eicher
Journal: Annals of Oncology (2021)
820TiP ENGOT-EN6/GOG-3031/NSGO-CTU-RUBY part 2: A phase III, randomized, double-blind, study of dostarlimab + carboplatin-paclitaxel followed by dostarlimab + niraparib versus placebo (PBO) + carboplatin-paclitaxel followed by PBO in recurrent or advanced endometrial cancer (EC)
Authors: M.R. Mirza, R.L. Coleman, L. Hanker, B. Slomovitz, G. Valabrega, L. DeMars, M. Walker, T. Duan, M. Powell
Journal: Annals of Oncology (2021)
Health screening needs independent regular re-evaluation
Authors: Fabienne G Ropers, Alexandra Barratt, Timothy J Wilt, Stuart G Nicholls, Sian Taylor-Phillips, Barnett S Kramer, Laura J Esserman, Susan L Norris, Lorna M Gibson, Russell P Harris, Stacy M Carter, Gemma Jacklyn, Karsten Juhl Jørgensen
Journal: BMJ (2021)

Changing circumstances may alter the benefit and risk profile of screening programmes. <b>Fabienne G Ropers and colleagues</b> propose a framework for re-evaluation to ensure continued public benefit
1396P Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: An exploratory analysis from the PRODIGY study
Authors: H-D. Kim, J.S. Lee, J.H. Yook, M.H. Ryu, Y-K. Park, J. Kim, Y-W. Kim, S-H. Noh, Y-K. Kang
Journal: Annals of Oncology (2021)
Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline
Authors: Deendyal Bhurta, Sandip B. Bharate
Journal: Medicinal Research Reviews (2021)

Abstract Kinases have gained an important place in the list of vital therapeutic targets because of their overwhelming clinical success in the last two decades. Among various clinically validated kinases, the cyclin‐dependent kinases (CDK) are one of the extensively studied drug targets for clinical development. Food and Drug Administration has approved three CDK inhibitors for therapeutic use, and at least 27 inhibitors are under active clinical development. In the last decade, research and development in this area took a rapid pace, and thus the analysis of scaffold diversity is essential for future drug design. Available reviews lack the systematic study and discussion on the scaffold diversity of CDK inhibitors. Herein we have reviewed and critically analyzed the chemical diversity present in the preclinical and clinical pipeline of CDK inhibitors. Our analysis has shown that although several scaffolds represent CDK inhibitors, only the amino‐pyrimidine is a well‐represented scaffold. The three‐nitrogen framework of amino‐pyrimidine is a fundamental hinge‐binding unit. Further, we have discussed the selectivity aspects among CDKs, the clinical trial dose‐limiting toxicities, and highlighted the most advanced clinical candidates. We also discuss the changing paradigm towards selective inhibitors and an overview of ATP‐binding pockets of all druggable CDKs. We carefully analyzed the clinical pipeline to unravel the candidates that are currently under active clinical development. In addition to the plenty of dual CDK4/6 inhibitors, there are many selective CDK7, CDK9, and CDK8/19 inhibitors in the clinical pipeline.